S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
Bank Accounts: Frozen! (Ad)
Germany, EU reach agreement in combustion engine row
Intel co-founder, philanthropist Gordon Moore dies at 94
"Prepare for Five Years of Famine" (Ad)
'What can we do?': Millions in African countries need power
Judge rules online archive's book service violated copyright
"Prepare for Five Years of Famine" (Ad)
Biden's moves on Alaska drilling, TikTok test young voters
Ruling halts oil exports from Iraq's Kurdish area via Turkey
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
Bank Accounts: Frozen! (Ad)
Germany, EU reach agreement in combustion engine row
Intel co-founder, philanthropist Gordon Moore dies at 94
"Prepare for Five Years of Famine" (Ad)
'What can we do?': Millions in African countries need power
Judge rules online archive's book service violated copyright
"Prepare for Five Years of Famine" (Ad)
Biden's moves on Alaska drilling, TikTok test young voters
Ruling halts oil exports from Iraq's Kurdish area via Turkey
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
Bank Accounts: Frozen! (Ad)
Germany, EU reach agreement in combustion engine row
Intel co-founder, philanthropist Gordon Moore dies at 94
"Prepare for Five Years of Famine" (Ad)
'What can we do?': Millions in African countries need power
Judge rules online archive's book service violated copyright
"Prepare for Five Years of Famine" (Ad)
Biden's moves on Alaska drilling, TikTok test young voters
Ruling halts oil exports from Iraq's Kurdish area via Turkey
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
Bank Accounts: Frozen! (Ad)
Germany, EU reach agreement in combustion engine row
Intel co-founder, philanthropist Gordon Moore dies at 94
"Prepare for Five Years of Famine" (Ad)
'What can we do?': Millions in African countries need power
Judge rules online archive's book service violated copyright
"Prepare for Five Years of Famine" (Ad)
Biden's moves on Alaska drilling, TikTok test young voters
Ruling halts oil exports from Iraq's Kurdish area via Turkey
NASDAQ:ABIO

ARCA biopharma - ABIO Stock Forecast, Price & News

$2.08
+0.05 (+2.46%)
(As of 03/24/2023 12:00 AM ET)
Add
Compare
Today's Range
$2.00
$2.08
50-Day Range
$2.02
$2.35
52-Week Range
$1.76
$2.70
Volume
33,578 shs
Average Volume
26,268 shs
Market Capitalization
$29.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

ABIO stock logo

About ARCA biopharma (NASDAQ:ABIO) Stock

ARCA biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of targeted therapies for cardiovascular diseases. The firm focuses on the cardiovascular pathophysiology, molecular genetics, and clinical development. Its product candidate, Gencaro is a pharmacologic beta-blocker and mild vasodilator, which is developed for the treatment of chronic heart failure and other indications. The company was founded by Michael R. Bristow and Christopher David Ozeroff in 1992 and is headquartered in Westminster, CO.

Receive ABIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ARCA biopharma and its competitors with MarketBeat's FREE daily newsletter.

ABIO Stock News Headlines

Biden To Unleash "Choke Point" Operation On America?
Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.
Frankie Muniz to race in ARCA Menards Series
Biden To Unleash "Choke Point" Operation On America?
Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.
James Flynn Joins ARCA biopharma Board of Directors
ABIO ARCA biopharma, Inc.
See More Headlines
Receive ABIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ARCA biopharma and its competitors with MarketBeat's FREE daily newsletter.

ABIO Company Calendar

Last Earnings
8/04/2021
Today
3/26/2023
Next Earnings (Estimated)
5/01/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ABIO
Employees
17
Year Founded
N/A

Profitability

Net Income
$-9,930,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.89 per share

Miscellaneous

Free Float
N/A
Market Cap
$29.54 million
Optionable
Not Optionable
Beta
1.47

Key Executives

  • Michael R. Bristow
    President, Chief Executive Officer & Director
  • Thomas A. Keuer
    Chief Operating Officer
  • C. Jeffrey Dekker
    Chief Financial Officer
  • Christopher David OzeroffChristopher David Ozeroff
    Secretary, Senior Vice President & General Counsel
  • Sharon Perry
    Vice President-Regulatory Affairs & Quality













ABIO Stock - Frequently Asked Questions

How have ABIO shares performed in 2023?

ARCA biopharma's stock was trading at $2.37 at the start of the year. Since then, ABIO shares have decreased by 12.2% and is now trading at $2.08.
View the best growth stocks for 2023 here
.

When is ARCA biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 1st 2023.
View our ABIO earnings forecast
.

How were ARCA biopharma's earnings last quarter?

ARCA biopharma, Inc. (NASDAQ:ABIO) posted its quarterly earnings results on Wednesday, August, 4th. The biopharmaceutical company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($2.37) by $2.03.

What is Michael R. Bristow's approval rating as ARCA biopharma's CEO?

1 employees have rated ARCA biopharma Chief Executive Officer Michael R. Bristow on Glassdoor.com. Michael R. Bristow has an approval rating of 100% among the company's employees. This puts Michael R. Bristow in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of ARCA biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ARCA biopharma investors own include Aurora Cannabis (ACBFF), MannKind (MNKD), Bausch Health Companies (BHC), Biocept (BIOC), Novavax (NVAX), AVEO Pharmaceuticals (AVEO), Gilead Sciences (GILD), iBio (IBIO), Nabriva Therapeutics (NBRV) and Synergy Pharmaceuticals (SGYP).

What is ARCA biopharma's stock symbol?

ARCA biopharma trades on the NASDAQ under the ticker symbol "ABIO."

Who are ARCA biopharma's major shareholders?

ARCA biopharma's stock is owned by a number of retail and institutional investors. Top institutional investors include BML Capital Management LLC (5.96%), Murchinson Ltd. (0.35%), Susquehanna International Group LLP (0.00%), Jane Street Group LLC (0.10%), SG3 Management LLC (0.00%) and Group One Trading L.P. (0.00%). Insiders that own company stock include Christopher David Ozeroff, Fund Lp Funicular and Robert E Conway.
View institutional ownership trends
.

How do I buy shares of ARCA biopharma?

Shares of ABIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ARCA biopharma's stock price today?

One share of ABIO stock can currently be purchased for approximately $2.08.

How much money does ARCA biopharma make?

ARCA biopharma (NASDAQ:ABIO) has a market capitalization of $29.54 million. The biopharmaceutical company earns $-9,930,000.00 in net income (profit) each year or ($0.69) on an earnings per share basis.

How can I contact ARCA biopharma?

ARCA biopharma's mailing address is 11080 CIRCLEPOINT ROAD SUITE 140, WESTMINSTER CO, 80020. The official website for the company is arcabio.com. The biopharmaceutical company can be reached via phone at (720) 940-2100, via email at derek.cole@arcabio.com, or via fax at 720-208-9261.

This page (NASDAQ:ABIO) was last updated on 3/26/2023 by MarketBeat.com Staff